Table 5. ABL1 gene mutations at diagnosis and relapse in ph+ ALL.
| Patients | TKI for front-line treatment | ABL1 mutations at diagnosis | Status | ABL1 mutations at relapse |
|---|---|---|---|---|
| Case 1 | dasatinib | F317L | Relapse | No mutation |
| Case 2 | dasatinib | L248V | Relapse | Y253H, E459K |
| Case 3 | imatinib | L523P, E505K | CCR | |
| Case 4 | nilotinib | No mutation | Relapse | T315I |
| Case 5 | imatinib | F317L | NR | |
| Case 6 | dasatinib | No mutation | Relapse | T315I |
| Case 7 | nilotinib | Y253 | Relapse | Y253, E255K |
| Case 8 | dasatinib | c.944C>T/p | Relapse | T315I |
| Case 9 | dasatinib | No mutation | Relapse | T315I |
| Case 10 | imatinib | No mutation | Relapse | T315I |